5-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer

E. Bolli, S. Saccomanno, G. Mondini, C. Aschele, A. Guglielmi, B. Ligas, M. Connio, A. Mori, R. Rosso, A. Sobrero, L. Tixi, V. Pugliese

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A total of 20 patients with advanced pancreatic adenocarcinoma were enrolled in a phase II trial testing the activity of 5-fluorouracil given at 370 mg/m2 as a rapid i. v. bolus for 5 consecutive days, preceded by a rapid i. v. bolus of 200 mg/m2 5-methyltetrahydrofolic acid. The treatment was repeated every 4 weeks. The median age of the patients was 68 years and their median Eastern Cooperative Oncology Group (ECOG) performance status was 1. There were 7 patients with locally advanced disease and 13 with distant metastases (median, 2 sites). A median of 3 monthly cycles of treatment (range, 1-7) were given, with a corresponding dose intensity of 396 mg/m2 per week (86% of that planned). No complete response, 1 partial response, and 8 cases of disease stabilization were obtained. In general the regimen was well tolerated, with only 2 patients suffering from grade 3 stomatitis or diarrhea; the most common toxicity was nausea, which was experienced by almost 50% of the patients. The combination of 5-methyltetrahydrofolate plus 5-fluorouracil appears as little effective in this disease as 5-fluorouracil plus 5-formyltetrahydrofolate (leucovorin). It is suggested that bolus 5-fluorouracil is so inactive as an "effector agent" against pancreatic cancer that its biochemical modulation with exogenous high-dose reduced folates cannot improve the therapeutic outcome produced by the fluoropyrimidine in these patients.

Original languageEnglish
Pages (from-to)339-342
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume35
Issue number4
DOIs
Publication statusPublished - Jul 1995

Fingerprint

Pancreatic Neoplasms
Fluorouracil
Leucovorin
Oncology
Folic Acid
Toxicity
Stomatitis
Stabilization
Modulation
Nausea
5-methyltetrahydrofolate
Diarrhea
Testing
Adenocarcinoma
Therapeutics
Neoplasm Metastasis

Keywords

  • 5-Fluorouracil
  • Pancreatic cancer
  • Reduced folates

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Bolli, E., Saccomanno, S., Mondini, G., Aschele, C., Guglielmi, A., Ligas, B., ... Pugliese, V. (1995). 5-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 35(4), 339-342. https://doi.org/10.1007/BF00689455

5-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer. / Bolli, E.; Saccomanno, S.; Mondini, G.; Aschele, C.; Guglielmi, A.; Ligas, B.; Connio, M.; Mori, A.; Rosso, R.; Sobrero, A.; Tixi, L.; Pugliese, V.

In: Cancer Chemotherapy and Pharmacology, Vol. 35, No. 4, 07.1995, p. 339-342.

Research output: Contribution to journalArticle

Bolli, E, Saccomanno, S, Mondini, G, Aschele, C, Guglielmi, A, Ligas, B, Connio, M, Mori, A, Rosso, R, Sobrero, A, Tixi, L & Pugliese, V 1995, '5-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer', Cancer Chemotherapy and Pharmacology, vol. 35, no. 4, pp. 339-342. https://doi.org/10.1007/BF00689455
Bolli E, Saccomanno S, Mondini G, Aschele C, Guglielmi A, Ligas B et al. 5-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology. 1995 Jul;35(4):339-342. https://doi.org/10.1007/BF00689455
Bolli, E. ; Saccomanno, S. ; Mondini, G. ; Aschele, C. ; Guglielmi, A. ; Ligas, B. ; Connio, M. ; Mori, A. ; Rosso, R. ; Sobrero, A. ; Tixi, L. ; Pugliese, V. / 5-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer. In: Cancer Chemotherapy and Pharmacology. 1995 ; Vol. 35, No. 4. pp. 339-342.
@article{3b22094b8f424912b1a46db76e7ab3c8,
title = "5-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer",
abstract = "A total of 20 patients with advanced pancreatic adenocarcinoma were enrolled in a phase II trial testing the activity of 5-fluorouracil given at 370 mg/m2 as a rapid i. v. bolus for 5 consecutive days, preceded by a rapid i. v. bolus of 200 mg/m2 5-methyltetrahydrofolic acid. The treatment was repeated every 4 weeks. The median age of the patients was 68 years and their median Eastern Cooperative Oncology Group (ECOG) performance status was 1. There were 7 patients with locally advanced disease and 13 with distant metastases (median, 2 sites). A median of 3 monthly cycles of treatment (range, 1-7) were given, with a corresponding dose intensity of 396 mg/m2 per week (86{\%} of that planned). No complete response, 1 partial response, and 8 cases of disease stabilization were obtained. In general the regimen was well tolerated, with only 2 patients suffering from grade 3 stomatitis or diarrhea; the most common toxicity was nausea, which was experienced by almost 50{\%} of the patients. The combination of 5-methyltetrahydrofolate plus 5-fluorouracil appears as little effective in this disease as 5-fluorouracil plus 5-formyltetrahydrofolate (leucovorin). It is suggested that bolus 5-fluorouracil is so inactive as an {"}effector agent{"} against pancreatic cancer that its biochemical modulation with exogenous high-dose reduced folates cannot improve the therapeutic outcome produced by the fluoropyrimidine in these patients.",
keywords = "5-Fluorouracil, Pancreatic cancer, Reduced folates",
author = "E. Bolli and S. Saccomanno and G. Mondini and C. Aschele and A. Guglielmi and B. Ligas and M. Connio and A. Mori and R. Rosso and A. Sobrero and L. Tixi and V. Pugliese",
year = "1995",
month = "7",
doi = "10.1007/BF00689455",
language = "English",
volume = "35",
pages = "339--342",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - 5-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer

AU - Bolli, E.

AU - Saccomanno, S.

AU - Mondini, G.

AU - Aschele, C.

AU - Guglielmi, A.

AU - Ligas, B.

AU - Connio, M.

AU - Mori, A.

AU - Rosso, R.

AU - Sobrero, A.

AU - Tixi, L.

AU - Pugliese, V.

PY - 1995/7

Y1 - 1995/7

N2 - A total of 20 patients with advanced pancreatic adenocarcinoma were enrolled in a phase II trial testing the activity of 5-fluorouracil given at 370 mg/m2 as a rapid i. v. bolus for 5 consecutive days, preceded by a rapid i. v. bolus of 200 mg/m2 5-methyltetrahydrofolic acid. The treatment was repeated every 4 weeks. The median age of the patients was 68 years and their median Eastern Cooperative Oncology Group (ECOG) performance status was 1. There were 7 patients with locally advanced disease and 13 with distant metastases (median, 2 sites). A median of 3 monthly cycles of treatment (range, 1-7) were given, with a corresponding dose intensity of 396 mg/m2 per week (86% of that planned). No complete response, 1 partial response, and 8 cases of disease stabilization were obtained. In general the regimen was well tolerated, with only 2 patients suffering from grade 3 stomatitis or diarrhea; the most common toxicity was nausea, which was experienced by almost 50% of the patients. The combination of 5-methyltetrahydrofolate plus 5-fluorouracil appears as little effective in this disease as 5-fluorouracil plus 5-formyltetrahydrofolate (leucovorin). It is suggested that bolus 5-fluorouracil is so inactive as an "effector agent" against pancreatic cancer that its biochemical modulation with exogenous high-dose reduced folates cannot improve the therapeutic outcome produced by the fluoropyrimidine in these patients.

AB - A total of 20 patients with advanced pancreatic adenocarcinoma were enrolled in a phase II trial testing the activity of 5-fluorouracil given at 370 mg/m2 as a rapid i. v. bolus for 5 consecutive days, preceded by a rapid i. v. bolus of 200 mg/m2 5-methyltetrahydrofolic acid. The treatment was repeated every 4 weeks. The median age of the patients was 68 years and their median Eastern Cooperative Oncology Group (ECOG) performance status was 1. There were 7 patients with locally advanced disease and 13 with distant metastases (median, 2 sites). A median of 3 monthly cycles of treatment (range, 1-7) were given, with a corresponding dose intensity of 396 mg/m2 per week (86% of that planned). No complete response, 1 partial response, and 8 cases of disease stabilization were obtained. In general the regimen was well tolerated, with only 2 patients suffering from grade 3 stomatitis or diarrhea; the most common toxicity was nausea, which was experienced by almost 50% of the patients. The combination of 5-methyltetrahydrofolate plus 5-fluorouracil appears as little effective in this disease as 5-fluorouracil plus 5-formyltetrahydrofolate (leucovorin). It is suggested that bolus 5-fluorouracil is so inactive as an "effector agent" against pancreatic cancer that its biochemical modulation with exogenous high-dose reduced folates cannot improve the therapeutic outcome produced by the fluoropyrimidine in these patients.

KW - 5-Fluorouracil

KW - Pancreatic cancer

KW - Reduced folates

UR - http://www.scopus.com/inward/record.url?scp=0028966177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028966177&partnerID=8YFLogxK

U2 - 10.1007/BF00689455

DO - 10.1007/BF00689455

M3 - Article

VL - 35

SP - 339

EP - 342

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 4

ER -